At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,500 enrolled
Drug / intervention
Olmesartan medoxomil +2 moredrug
Likely dose
Olmesartan medoxomil 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension
In Brief
A Phase 3 clinical trial evaluating Olmesartan medoxomil, Amlodipine, and 1 other intervention for Hypertension. Completed, enrolled 2,500 participants across 232 sites in 2 countries.
Detailed Summary
To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionApr 2009
Study CompletionDec 2009
TodayJul 2026
First PostedApr 1, 2008
Enrollment StartMay 1, 2008
Primary CompletionApr 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.3 years ago
Interventions
Olmesartan medoxomildrug
40mg olmesartan medoxomil
Amlodipinedrug
Amlodipine 10mg
Hydrochlorothiazidedrug
Hydrochlorothiazide 25mg